Top Chinese health official expressed concerns over the low effectiveness of Chinese inactive vaccines, as countries rely on Chinese jabs for the mass inoculation campaign -- from Chile in South America to Hungary in Eastern Europe suffered setbacks in controlling the raging outbreaks. While the vaccination rate in these countries powered ahead of most, case number and hospitalization rate – fueled by variants has been surging, putting Chinese vaccines' protection against virus mutations under scrutiny. But countries with mRNA vaccines as the major source – including Israel, UK, and the US, seem in entirely different ballgames. The vaccines have helped flatten the curve and send the new infections in decline.
SinoPharm vaccine played a critical part in Hungary's vaccination campaign. With a population of 9 million, Hungary has bought 5 million doses of the SinoPharm vaccine and inoculated 24.9% of the people as of April 7, the second-highest among EU countries and well ahead of Canada's 18.7%. However, according to Our World in Data, Hungary endured the worst pandemic crisis among European countries in early April, with infection per million people far exceeding Canada's 180 and EU's 331. Meanwhile, it had fetched the death rate of 209 deaths per 100,000 people, the world's second-highest Covid death rate per capita.
智利的疫情感染率曾在四月初激增，而与此同时，智利的疫苗的接种运动势头强劲，其接种率在全球名列前茅。SinoVac疫苗占该国接种疫苗 的93%， 其一剂疫苗接种高达40%， 二剂为27%，高于纽约市接种率的39% 和26%。截止4月7日，纽约的新病例和住院率都有所下降，而智利的新案病例却在上升，同时住院率和死亡率都高居不下。
Covid infections surged in Chile in early April while its vaccine rollout gained momentum, ranking among one of the top countries in the world. With SinoVac accounting for 93% of inoculated shots, its one-dose inoculation rate reached as high as 40% and the second-dose 27%, even higher than 39% and 26% of New York City respectively. While a 14-day average of new cases and hospitalization dropped in New York as of April 7, the infection rate in Chile soared while hospitalization and death rates refused to budge.
The efficacy of the vaccines has made all the differences. Inactive vaccines' general protection lags significantly behind mRNA shots. SinoPharm has not provided completed and detailed clinical trial data, while SinoVac vaccines' data – from real-world effectiveness to clinical trial results -- were all over the place. A clinical trial for SinoVac in Turkey had published the results of 91%, before Indonesia's testing showed 65.3%. In Brazil, a test by Butantan Institute announced a 78% efficacy rate in early Jan, while its latest released results revealed a disappointing rate of 50.4%. More shockingly, a study published by the University of Chile has shown the SinoVac vaccine was 56.6% effective two weeks after the second dose but only 3% effective after one shot.
Meanwhile, the mRNA vaccines have shown consistent results across the board. The collected data from Israel, the world's vaccination campaign leader, confirmed the vaccine's highly effective clinical trial results. mRNA vaccine has led Israel to achieve a stunning victory in the Covid war as the only vaccine source. Even without strict lockdown measures, Israel recorded no new daily Covid-19 deaths for the first time in ten months on April 25. Israel data has shown that Pfizer vaccines' effectiveness reached as high as 97% in preventing symptomatic Covid cases, hospitalization, and death tolls, and 94% against asymptomatic infections.
The mRNA vaccines have also proven the most effective against variants among all vaccines. According to the latest study, the vaccine-induced antibodies are powerful enough to bind multiple sites in the virus so that even if a mutation compromises the binding in one site, the antibody’s ability to target the remaining sites remains intact.
China is on course to produce its version of mRNA vaccines, with clinical trials undergoing and the delivery date set by the end of the year. The efforts have underscored China's recognition of the mRNA vaccines' significant values and its remarkable success in the global vaccine race.
我们鼓励所有读者在我们的文章和博客上分享意见。We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, and please keep your comments relevant and respectful. Visit the FAQ page for more information.